XTL Biopharmaceuticals Ltd.
NASDAQ: XTLB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Noam Band
- Employees
- 10
- Headquarters
- Ramat Gan, Israel
- IPO year
- 2005
- Market cap
- $6.6M
- Website
- https://www.xtlbio.com
Loading XTLB…
Loading profile data…Frequently asked questions about XTLB
What does XTL Biopharmaceuticals Ltd. (XTLB) do?
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement...
Where does XTLB trade?
XTL Biopharmaceuticals Ltd. (XTLB) trades on the NASDAQ Capital Market.
What sector is XTLB in?
XTL Biopharmaceuticals Ltd. (XTLB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of XTL Biopharmaceuticals Ltd.?
Noam Band is the chief executive officer of XTL Biopharmaceuticals Ltd. (XTLB).
Where is XTL Biopharmaceuticals Ltd. headquartered?
XTL Biopharmaceuticals Ltd. is headquartered in Israel.
Does XTLB pay a dividend?
XTL Biopharmaceuticals Ltd. (XTLB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XTLB go public?
XTL Biopharmaceuticals Ltd. (XTLB) completed its initial public offering in 2005.
Is XTLB an ADR?
Yes — XTLB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. XTL Biopharmaceuticals Ltd. reporting and dividends follow the underlying issuer.